Ohio is currently home to 3309 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT05963074
Recruiting
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse events (AEs).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Oncology Hematology Care, Cincinnati, Ohio
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma
Register for Updates
Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT05961839
Recruiting
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Cleveland Clinic Foundation, Cleveland, Ohio
Conditions: Acute Myeloid Leukemia, High-Risk and Very High-Risk Myelodysplastic Syndromes
Register for Updates
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
NCT05949684
Recruiting
The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Myelodysplastic Syndromes
Register for Updates
BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants
NCT05943106
Recruiting
The purpose of this study is to assess the safety, tolerability, and efficacy profile of durvalumab + BCG (induction and maintenance) combination therapy in adult United States participants with a histologically confirmed diagnosis of high-risk non-muscle-invasive bladder cancer (NMIBC), who have received no prior systemic therapy for NMIBC, and who are BCG-naïve.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
06/18/2024
Locations: Research Site, Cincinnati, Ohio
Conditions: Non-Muscle- Invasive Bladder Cancer
Register for Updates
A Registry to Gather Real World Use Data on the Cerene® Cryotherapy Device
NCT05922657
Recruiting
Channel Medsystems, Inc., the manufacturer of the Cerene® Cryotherapy Device (Cerene), is initiating a prospective, observational registry, the Progress registry, to gather data during real world utilization of the Cerene® Cryotherapy Device (Cerene). The primary objective of this registry is to bridge the gap between clinical results and outcomes achieved and reported during the pivotal study of Cerene and those obtained during its real-world use.
Gender:
Female
Ages:
25 years and above
Trial Updated:
06/18/2024
Locations: Axia Women's Health / Seven Hills Women's Health Centers, Cincinnati, Ohio
Conditions: Heavy Menstrual Bleeding, Abnormal Uterine Bleeding, Menorrhagia
Register for Updates
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
NCT05897320
Recruiting
The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/18/2024
Locations: Childrens Hospital Medical Center of Akron, Akron, Ohio
Conditions: Episodic Migraine
Register for Updates
A Switch Study From High-Sodium Oxybate to XYWAV to Evaluate Changes in Blood Pressure in Participants With Narcolepsy
NCT05869773
Recruiting
The aim of this study is to quantify the change in blood pressure when participants with narcolepsy treated with high-sodium oxybate are transitioned to XYWAV, a low-sodium oxybate. The results of this study may provide health care providers (HCPs), patients, and payers with important new information regarding BP changes related to differences in sodium content between available oxybates for the treatment of narcolepsy.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
06/18/2024
Locations: Intrepid Research, LLC, Cincinnati, Ohio
Conditions: Narcolepsy
Register for Updates
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies
NCT05846659
Recruiting
Phase 2, open-label, multicenter, randomized study comparing the safety and efficacy of personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR) combined with immune checkpoint inhibitor (ICI) immunotherapy (PULSAR-ICI) + IMSA101 and PULSAR-ICI alone in patients with oligoprogressive solid tumor malignancies after prior anti-cancer therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio
Conditions: Oligoprogressive
Register for Updates
Direct Access Carotid Artery Stenting Using the Neuroguard IEP System (PERFORMANCE III)
NCT05845710
Recruiting
The PERFORMANCE III study is a prospective, multicenter single-arm, open label study to evaluate the safety and effectiveness of the Neuroguard IEP® Direct System for the treatment of carotid artery stenosis in subjects at elevated risk for carotid endarterectomy (CEA). Eligible patients greater than or equal to 20 years of age and less than or equal to 80 years of age, are those who have been diagnosed with either de-novo atherosclerotic or post CEA restenotic lesion(s) in the internal carotid... Read More
Gender:
All
Ages:
Between 20 years and 80 years
Trial Updated:
06/18/2024
Locations: TriHealth (Bethesda North Hospital), Cincinnati, Ohio
Conditions: Carotid Stenosis, Carotid Artery Diseases
Register for Updates
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
NCT05827016
Recruiting
The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Oncology Hematology Care, Inc. - Cincinnati - Galbraith Rd, Cincinnati, Ohio
Conditions: Multiple Myeloma
Register for Updates
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
NCT05814627
Recruiting
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how safe and effective upadacitinib is in treating RA when compared to adalimumab in adult participants with inadequate response or intolerance to one TNF-inhibitor who are on a stable dose of methotrexate (MTX). Adverse events and change in disease activity will be assessed. Upadacitinib is an approved drug for the treatment of RA. This study is doubl... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Paramount Medical Research and Consulting /ID# 254048, Middleburg Heights, Ohio
Conditions: Rheumatoid Arthritis
Register for Updates
A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT05811351
Recruiting
The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.
Gender:
All
Ages:
60 years and above
Trial Updated:
06/18/2024
Locations: Cincinnati Eye Institute, Cincinnati, Ohio
Conditions: Geographic Atrophy
Register for Updates